Corvus Pharmaceuticals In... (CRVS)
Corvus Pharmaceuticals Statistics
Share Statistics
Corvus Pharmaceuticals has 68.14M shares outstanding. The number of shares has increased by 8.93% in one year.
| Shares Outstanding | 68.14M |
| Shares Change (YoY) | 8.93% |
| Shares Change (QoQ) | 6.04% |
| Owned by Institutions (%) | 56.48% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 36 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 5.34M, so 7.84% of the outstanding shares have been sold short.
| Short Interest | 5.34M |
| Short % of Shares Out | 7.84% |
| Short % of Float | 9.54% |
| Short Ratio (days to cover) | 6.47 |
Valuation Ratios
The PE ratio is -5.24 and the forward PE ratio is -19.97. Corvus Pharmaceuticals's PEG ratio is -0.06.
| PE Ratio | -5.24 |
| Forward PE | -19.97 |
| PS Ratio | 0 |
| Forward PS | 3.2 |
| PB Ratio | 10.02 |
| P/FCF Ratio | -12.83 |
| PEG Ratio | -0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Corvus Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.03.
| Current Ratio | 1.54 |
| Quick Ratio | 1.54 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.04 |
| Interest Coverage | -15.1 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,009,451.61 |
| Employee Count | 31 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 102.89% in the last 52 weeks. The beta is 0.7, so Corvus Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | 102.89% |
| 50-Day Moving Average | 3.74 |
| 200-Day Moving Average | 5.21 |
| Relative Strength Index (RSI) | 50.66 |
| Average Volume (20 Days) | 724,970 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.55M |
| Net Income | -62.29M |
| EBITDA | -27.55M |
| EBIT | -60.47M |
| Earnings Per Share (EPS) | -1.02 |
Balance Sheet
The company has 8.74M in cash and 1.12M in debt, giving a net cash position of 7.62M.
| Cash & Cash Equivalents | 8.74M |
| Total Debt | 1.12M |
| Net Cash | 7.62M |
| Retained Earnings | -397.01M |
| Total Assets | 68.91M |
| Working Capital | 19M |
Cash Flow
In the last 12 months, operating cash flow was -25.42M and capital expenditures 0, giving a free cash flow of -25.42M.
| Operating Cash Flow | -25.42M |
| Capital Expenditures | n/a |
| Free Cash Flow | -25.42M |
| FCF Per Share | -0.42 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRVS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CRVS is $15, which is 327.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 327.4% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -5.12 |
| Piotroski F-Score | 1 |